Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
Expert Rev Anti Infect Ther. 2015 Apr;13(4):409-16
Authors: Wu G, Truong J, Lee S, Elnadoury O, Kuan W, Abraham T, Wu A, Liu M
Oritavancin, a lipoglycopeptide antibiotic, recently received US FDA approval for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). Oritavancin, unlike other intravenous antibiotics that are currently available for the treatment of ABSSSI (e.g., vancomycin, daptomycin, telavancin, dalbavancin), offers the option of a single-dose complete regimen. The dosing schedule of oritavancin eliminates the need for an indwelling catheter and introduces the possibility of avoidance of a hospital admission; although, treatment in non-hospital settings has not been adequately evaluated in clinical trials. The availability of oritavancin adds another agent to our antibiotic armamentarium providing dosing flexibility and an alternative treatment option for treatment of ABSSSI caused by susceptible bacteria, including methicillin-resistant Staphylococcus aureus.
PMID: 25661747 [PubMed - in process]